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Abstract 
In the past few years, the world has witnessed the surge of new psychoactive substances 
(NPS) and the rise in their popularity within the club scene. The interest in these substances 
derived from their capacity to elicit similar effects to those of classic stimulants such as 
cocaine and amphetamines, with the advantages of the relative ease to obtain and the legal 
status. This fostered the unregulated rise of substances like mephedrone and 3,4-
methylenedioxypyrovalerone (MDPV), but recent legislation has also banned these drugs 
in several countries. Consequently, new synthetic phenethylamines appeared on the drug 
market, untested for human safety. 
This works aimed to investigate the cytotoxic potential of four synthetic cathinones 
(butylone, buphedrone, 3,4-dimethylmethcathinone [3,4-DMMC] and 4-
fluoromethcathinone [4-FMC]) and two benzofurans (6-(2-aminopropyl)benzofuran [6-APB] 
and 5-(2-aminopropyl)benzofuran) [5-APB] that have recently emerged in the described 
context.  
When considering the toxicological assessment of new drugs, the liver is an organ that 
stands out for its pivotal role in the metabolism of these toxicants; therefore, we chose three 
different in vitro models for the hepatocyte to accomplish our aim: primary rat hepatocytes 
and the immortalized cell lines HepaRG and HepG2. Concentration-response curves for all 
drugs were established in the three cell models, using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay; cells models were exposed for 24h to a wide 
range of concentrations. Then, a set of oxidative stress endpoints and energetic status were 
evaluated in primary rat hepatocytes, by testing each drug at the respective EC20, EC40, 
EC50 and EC70. 
For all in vitro models, 3,4-DMMC was the most toxic substance (EC50 0.16 mM in primary 
rat hepatocytes; 0.7 mM in HepaRG cells; and 0.62 mM in HepG2 cells). 4-FMC was the 
least toxic drug for primary rat hepatocytes (EC50 2.21 mM) and buphedrone was the least 
toxic compound for the cell lines (EC50 9.62 mM and 13.67 mM for HepaRG and HepG2 
cells, respectively). Additionally, 3,4-DMMC and 4-FMC elicited a notorious increase in the 
production of reactive oxygen and nitrogen species; all substances were capable of 
inducing a concentration-dependent shortage in antioxidant defences (glutathione) and of 
interfering with the normal energetic status. 
Our work provides the first evidence of the hepatotoxic potential of these new psychoactive 
substances and sheds some light on the molecular mechanisms underlying the observed 
effects. 
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Resumo 
Nos últimos anos, o mundo testemunhou o surgimento de novas substâncias psicoativas 
(NPS) e o aumento da sua popularidade dentro do ambiente de discoteca. O interesse 
nestas substâncias prende-se com a sua capacidade de provocar efeitos semelhantes aos 
de estimulantes clássicos, como a cocaína e as anfetaminas, com as vantagens da relativa 
facilidade de obtenção e o estatuto legal. Isto fomentou o aumento descontrolado de 
substâncias como a mefedrona e 3,4-metilenodioxipirovalerona (MDPV), mas a legislação 
recente proibiu também estas drogas em vários países. Como consequência, novas 
feniletilaminas sintéticas apareceram no mercado de drogas, sem que tenham sido 
testadas para a segurança humana. 
O objetivo deste trabalho foi investigar o potencial citotóxico de quatro catinonas sintéticas 
(butilona, bufedrona, 3,4-dimetilmetcatinona [3,4-DMMC] e 4-fluorometcathinona [4-FMC]) 
e dois benzofuranos (6-(2-aminopropil)benzofurano [6-APB] e 5-(2-
aminopropil)benzofurano) [5-APB] que surgiram recentemente no contexto descrito. 
Quando se considera a avaliação toxicológica de novas drogas, o fígado é um órgão que 
se destaca pelo seu papel central no metabolismo destas substâncias tóxicas; portanto, 
nós selecionámos três modelos in vitro diferentes de hepatócito para alcançar o nosso 
objetivo: hepatócitos primários de rato e as linhas celulares imortalizadas HepaRG e 
HepG2. As curvas de concentração-resposta para todas as drogas foram determinadas 
nos três modelos de células, utilizando o ensaio de 3-(4,5-dimetiltiazol-2-il)-2,5-
difeniltetrazólio (MTT); os modelos celulares foram expostos durante 24 horas para uma 
vasta gama de concentrações. De seguida, um conjunto de marcadores de stress oxidativo 
e do estado energético foram avaliados nos hepatócitos primários de rato, pelo ensaio de 
cada fármaco nas respetivas EC20, EC40, EC50 e EC70. 
Para todos os modelos in vitro, a 3,4-DMMC foi a substância mais tóxica (EC50 0,16 mM 
em hepatócitos primários de rato; 0,7 mM na linha celular HepaRG; e 0,62 mM na linha 
celular HepG2). A 4-FMC foi a droga menos tóxica para os hepatócitos primários de rato 
(EC50 2,21 mM) e a bufedrona o composto menos tóxico para as linhas celulares (EC50 9,62 
mM e 13,67 mM nas linhas celulares HepG2 e HepaRG, respetivamente). Para além disso, 
3,4-DMMC e 4-FMC despoletaram um aumento notório na produção de espécies reativas 
de oxigénio e de azoto; todas as substâncias foram capazes de induzir uma escassez 
dependente da concentração das defesas antioxidantes (glutationa) e de interferir com o 
estado energético normal. 
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O nosso trabalho fornece a primeira evidência do potencial hepatotóxico destas novas 
substâncias psicoativas e elucida os mecanismos moleculares subjacentes aos efeitos 
observados. 
Palavras-chave: hepatócitos, citotoxicidade, stress oxidativo, catinonas sintéticas, 
“benzofury”  
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Introduction 
New psychoactive substances (NPS) have been on the rise since their introduction in the 
drug markets, with the number of new substances and seizures increasing at alarming 
rates. The 2016 European Drug Report points that, in 2015, 98 new drugs were detected, 
which accounts for a total of 560 NPS monitored by de European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA), 70% of which have appeared in the last 5 years 
(EMCDDA, 2016). Two of the most prominent groups of NPS are synthetic cathinones and 
benzofurans. As popularity of novel derivatives increased, the number of intoxications 
related to the substances of these groups, including some deaths, has risen (Adamowicz et 
al., 2014; Batisse et al., 2014; Borek and Holstege, 2012; Carbone et al., 2013; Chan et al., 
2013; Kramer et al., 2016; Pearson et al., 2012; Thornton et al., 2012; Wood et al., 2010; 
Wright et al., 2013) but their toxicological spectrum are far from being fully elucidated and 
information on the molecular mechanisms responsible by the detrimental effects of NPS is 
yet to be disclosed. 
Therefore, to provide some potential insight into the reasons behind random occurrence of 
extreme toxicity after consumption of these NPS and to increase the knowledge necessary 
to aid diagnostics and treatment of intoxications, our group sought to investigate the 
hepatotoxic effects of a few synthetic cathinone derivatives (butylone, buphedrone, 3,4-
dimethylmethcathinone [3,4-DMMC], and 4-fluoromethcathinone [4-FMC or flephedrone]) 
and benzofurans (6-(2-aminopropyl)benzofuran (6-APB) and 5-(2-aminopropyl)benzofuran) 
(5-APB). 
 
1. Synthetic cathinones 
Synthetic cathinones derive from the naturally occurring alkaloid cathinone, that comes from 
the evergreen plant Catha edulis. They are known by the street name of bath salts and have 
been marketed as legal alternatives to classical stimulants such as amphetamines. The 
majority of these substances are manufactured in China and South East Asia and then 
shipped to distributors, who are in charge of packaging, selling and, eventually, tampering 
(common adulterants include paracetamol, caffeine and piperazines). The packaging often 
includes the warning ‘not for human consumption’, as well as names such as Ivory Wave, 
Bloom and Vanilla Sky (German et al., 2014; Valente et al., 2014). 
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1.1. Chemistry 
The chemical structure of cathinone is very similar to that of amphetamine, with an 
additional β-keto group on the amino alkyl chain (Fig. 1).  
 
Figure 1 Chemical structure of amphetamine, cathinone and the synthetic cathinones butylone, buphedrone, 4-
fluoromethcathinone and 3,4-dimethylmethcathinone 
This group is present in all synthetic cathinones, which are synthesised by adding extra 
groups to the basic cathinone structure (Valente et al., 2014). Aside from the ketone group, 
synthetic cathinones may have other functional groups, and their presence or absence 
classifies the compound in one of four families (Fig. 1):  
 N-alkylated synthetic cathinones (e.g. buphedrone, 3,4-dimethylmethcathinone [3,4-
DMMC] and 4-fluoromethcathinone [4-FMC or flephedrone]); 
 synthetic cathinones with a 3,4-methylenedioxy ring (e.g. butylone); 
 N-pyrrolidine substituted synthetic cathinones; and 
 cathinone derivatives that present the chemical characteristics of the former two 
groups, i.e. n-pyrrolidine substituted synthetic cathinones with a 3,4-methylenedioxy 
ring. 
The ketone group of synthetic cathinones is responsible for a decrease in polarity, when 
comparing with its amphetamine counterpart. However, analogues displaying the 
pyrrolidine ring at the amino group present higher lipophilicity. The increase or decrease in 
polarity will affect the compounds capability to cross the blood-brain barrier (BBB) and to 
reach the brain. 
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1.2. Pharmacodynamics 
Upon reaching the brain, cathinone derivatives will interact with the monoamine reuptake 
transporters, functioning as substrates or blockers and inducing dopamine (DA), serotonin 
(5-HT) and noradrenaline (NA) release. The distinct capacity that these drugs have for 
inducing monoamine release and for interacting with monoamine transporters led to the 
classification of synthetic cathinones in three classes (Table 1) (Valente et al., 2014; 
Zawilska and Wojcieszak, 2013). 
Table 1 Classification of synthetic cathinones according to the pharmacological action. MDMA, 3,4-
methylenedioxymethamphetamine. 5-HT, serotonin. DA, dopamine. 4-FMC, 4-fluoromethcathinone 
Class Mode of action 
Cocaine-MDMA-mixed cathinones  
(e.g. butylone and buphedrone) 
Act as non-selective monoamine reuptake 
inhibitors and induce 5-HT release 
Methamphetamine-like cathinones  
(e.g. 4-FMC) 
Induce DA release and inhibit catecholamine 
reuptake 
Pyrovalerone cathinones 
Do not provoke monoamine release. Act as 
weak 5-HT reuptake inhibitors and potent 
catecholamine reuptake inhibitors 
 
Different synthetic cathinones will display different affinities for monoamine transporters, 
even if they belong to the same class. Accordingly, 4-FMC is more capable of inhibiting the 
NA transporters (NAT) than buphedrone or butylone, but butylone has a higher inhibitor 
potency for the DA and 5-HT transporters (DAT and SERT, respectively) than 4-FMC and 
buphedrone (Simmler et al., 2013; Simmler et al., 2014). It is also known that cathinone 
derivatives are capable of inhibiting monoamine oxidase (MAO) and have increased affinity 
for the isoform MAO-B, the main enzyme responsible for degrading DA. Additionally, the 
methyl group present at the α-carbon prevents the degradation of these compounds by 
MAO (Kelly, 2011; Valente et al., 2014). 
 
1.3. Pharmacokinetics 
The most common administration routes for synthetic cathinones are oral ingestion and 
nasal inhalation (‘snorting’), but many other methods can be employed (such as rectal 
insertion, intramuscular or intravenous injection) (Prosser and Nelson, 2012). 
After absorption, the compounds will undergo extensive phase I metabolism (Kelly, 2011). 
Buphedrone, 3,4-DMMC, and 4-FMC display the common metabolic pathways of N-
4 
 
alkylated synthetic cathinones, which include N-demethylation and reduction of the ketone 
group (Fig. 2) (Uralets et al., 2014). 
 
 
 
 
 
 
 
 
A detailed study regarding the metabolism of 3,4-DMMC after administration of 
approximately 30 mg of the drug showed the production of three main urine metabolites, 
3,4-dimethylcathinone (DMC), β-hidroxy-DMMC, β-hidroxy-DMC, and other putative 
metabolites of unknown structure (Fig. 3). Furthermore, partial conjugation of the parent 
drug and its metabolites is a possibility, since the concentration of metabolites increased 
following urine hydrolysis (Tyrkko et al., 2013). 
 
 
 
 
 
 
 
 
 
Figure 2 Main metabolic pathways of N-alkylated synthetic cathinones. Reactions are 1 - N-dealkylation, 2 - βketo 
reduction and 3- ring hydroxylation (except for buphedrone). 
Figure 3 Metabolic pathways and metabolites of 3,4-dimethylmethcathinone (3,4-DMMC). Reactions 1 and 2 
are β-keto reduction and N-demethylation, respectively 
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In what concerns 4-FMC, the drug is expected to be more resistant to metabolism due to 
the presence of the C-F bond, which increases the molecule stability and therefore the 
resistance to cleavage (Kelly, 2011). A study in rats regarding the metabolism of the isomer 
3-fluoromethcathinone (3-FMC) provided information on the metabolic pathways of the 
drugs, which include ring hydroxylation, reduction of the ketone group, and N-demethylation 
(Fig. 4). 
 
Figure 4 Metabolic pathways of 3-fluoromethcathinone (3-FMC). Reactions are 1- ring hydroxylation, 2- β-keto reduction, 3- 
N-demethylation, and 4- conjugation with glucuronic acid (adapted from Meyer (2012)) 
 
3-FMC can be excreted in the non-metabolized form, after reduction of the ketone group, 
or as a conjugate with glucuronic acid (Meyer et al., 2012). 
Butylone also suffers reduction of the β-keto group and N-dealkylation (the last one appears 
to be a minor pathway for synthetic cathinones). Additionally, demethylenation of the 
methylenedioxy ring, followed by O-methylation by catechol O-methyl transferase (COMT) 
also occurs (Fig.5). The resulting metabolites can be conjugated with sulphate or 
glucuronide and are excreted with the parent drug (Zaitsu et al., 2011). 
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Figure 5 Metabolic pathway of butylone. Reactions; 1 – β-keto reduction, 2 – demethylenation, 3 – O-methylation and 4 – N-
dealkylation. 
 
1.4. Subjective effects in human 
Among the main pleasant effects of synthetic cathinone, abusers describe euphoria, 
increased in energy, motivation, and empathy. However, undesired effects will also occur; 
the most reported are associated with sympathomimetic syndrome and include agitation, 
hypertension, tachycardia, seizures, mydriasis, and hyperthermia (Coppola and Mondola, 
2012; Katz et al., 2014; Kelly, 2011; Prosser and Nelson, 2012; Valente et al., 2014). 
 
1.5. Toxicity 
Synthetic cathinones have been documented to cause toxicity at numerous levels. In what 
concerns neurotoxicity, 3-FMC has been proven capable of inhibiting cellular growth of 
mouse hippocampal cells (Siedlecka-Kroplewska et al., 2014). Toxicity towards other 
important organs needs further investigation, but the already existing studies show that 
cathinone derivatives elicit toxic effects on heart (increased heart rate, blood pressure, and 
mean arterial pressure in rats), liver (induction of concentration-dependent death in isolated 
hepatocytes), kidneys (acute kidney injury in abusers), and muscle tissue (rhabdomyolysis); 
and are capable of inducing hyperthermia, which in its turn may aggravate all the other 
deleterious effects, as already observed for amphetamines (Araujo et al., 2015; da Silva et 
al., 2014a; Dias da Silva et al., 2013c; Fantegrossi et al., 2013; Kiyatkin et al., 2015; Meng 
et al., 2012; O'Connor et al., 2015; Sutamtewagul et al., 2014; Valente et al., 2016; Valente 
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et al., 2015). The mechanisms through which these compounds trigger toxicity need further 
investigation, but it was already shown that synthetic cathinones cause an increase in 
oxidative stress, hamper cellular energetics and Ca2+ homeostasis, cause mitochondrial 
dysfunction and apoptosis (Valente et al., 2016; Valente et al., 2015). It is still necessary 
and paramount to clarify whether these effects are extensible to all synthetic cathinones 
and if so, at which levels they negatively affect abusers. 
 
2. Benzofurans 
Another popular group of NPS, which are also synthetic phenethylamines, is benzofurans. 
The most commonly consumed benzofurans are 5-(2-aminopropyl)benzofuran (5-APB) and 
6-(2-aminopropyl)benzofuran (6-APB), substances that will also be addressed in this work. 
These compounds appeared in the drug scene in 2010/2011 and are best known under the 
name ‘benzo fury’ (Zawilska, 2015). They were first synthesized in 1993, as non-neurotoxic 
analogues of methylenedioxymethamphetamine (MDMA). 
2.1. Chemistry 
 Structurally, benzofurans are closely related to the MDMA active metabolite 
methylenedioxyamphetamine (MDA), with a furan instead of a methylenedioxy ring (Fig. 6) 
(Jebadurai et al., 2013; Nugteren-van Lonkhuyzen et al., 2015). 
 
Figure 6 Chemical structure of benzofurans and of their amphetamine analogues. 
 
2.2. Patterns of abuse 
While 5-APB misuse started in United Kingdom in 2010, first 6-APB reports occurred in 
Hungary in the subsequent year. The trading of these drugs rapidly increased through 
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internet, in particular for 6-APB (EMCDDA, 2011). The most common route of administration 
is oral ingestion; inhalation is described as very painful (Jebadurai et al., 2013). 
 
2.3. Pharmacodynamics 
In a similar fashion to MDMA, 6-APB and 5-APB act primarily as potent monoamine 
transporter inhibitors, and are also capable of inducing monoamine release and of 
interacting with the trace amine-associated receptor 1 (TAAR1), which is thought to 
underline locomotion and the neurochemical stimulant effects of these drugs (Rickli et al., 
2015). Additionally, both benzofurans demonstrated to be partial agonists of the 
serotoninergic receptors 5-HT2A, 5-HT2B and 5-HT2C. This binding is particularly important 
since 5-HT2A is associated with the hallucinogenic properties of the drugs and 5-HT2B 
stimulation can increase the risk of cardiotoxicity by inducing proliferation of cardiac cells of 
the interstitial valve, thus leading to drug-induced heart valve fibrosis (Iversen et al., 2013; 
Rickli et al., 2015). The analogues 6-APB and 5-APB were also capable of binding to α-
adrenoreceptors; of particular interest, the high affinity of 6-APB to α2A receptor, is 
responsible by intense release of NA and, consequently, sympathomimetic effects (Rickli 
et al., 2015). In addition, 5-APB proved to be capable of inducing vasoconstriction, an effect 
mediated by 5-HT2A receptors, and associated to increased DA brain levels (Dawson et al., 
2014). 
 
2.4. Pharmacokinetics 
The main metabolites of 6-APB and 5-APB are 4-carboxymethyl-3-hydroxy amphetamine 
and 3-carboxymethyl-4-hydroxy amphetamine, respectively. The main metabolic pathways 
involved include ring cleavage by hydroxylation and reduction of the resulting unsaturated 
aldehyde, which can then be oxidized to a carboxylic acid or reduced to an alcohol. Some 
minor metabolic steps include deamination of both 6-APB and 5-APB and di-hydroxylation 
of 5-APB (Fig. 7) (Welter-Luedeke and Maurer, 2015). 
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Figure 7 Metabolic pathways of 5-APB. Reactions: 1 - ring hydroxylation, 2 - reduction of unsaturated aldehyde, 3 - oxidation 
to carboxylic acid, 4 - reduction to alcohol, 5 - deamination and 6 - further hydroxylation of the hidroxy metabolite 
 
2.5. Subjective effects in humans 
Benzofurans are ingested mostly due to their ability to induce entactogenic and stimulant 
effects, such as MDMA but with higher potency (Zawilska, 2015).The adverse effects 
caused by these substances are in league those elicited by MDMA and MDA, with users 
reporting tachycardia, agitation, nausea, anxiety, jaw and teeth clenching, and mydriasis 
(Jebadurai et al., 2013; Zawilska, 2015). 
 
2.6. Toxicity 
Of concern, 5-APB and 6-APB have been implicated in a number of deaths in the UK, but 
in the majority of the cases there were other substances present (Nugteren-van Lonkhuyzen 
et al., 2015). A recent study evaluated the cytotoxic potential of 5-APB in isolated rat 
hepatocytes and concluded that this substance has the ability to induce time-dependent 
cytotoxicity, to increase cellular oxidative stress, and to interfere with mitochondrial 
homeostasis (Nakagawa et al., 2016). It is clear that benzofurans have the potential to 
cause severe toxicity, but the mechanisms involved are yet to be fully unravelled. Therefore, 
it is paramount for user safety the conduction of more studies pertaining to benzofurans 
toxicity.  
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Aim 
Research on the toxicity of NPS is imperative because the vast majority of these substances 
are marketed without testing their safety prior to human consumption. Synthetic 
phenethylamines comprise a great part of the new substances that reach the drug markets, 
and every time a substance becomes prohibited, new derivatives are synthesized to fill its 
gap. With the intense rate of production of NPS, it is difficult to accompany their appearance 
in the drug scene with satisfactory knowledge on the mechanisms of toxicity. However, in 
virtue of the structural similarity between banned and newly synthesised drugs, information 
on toxicity of the previously legal drugs is a useful tool. 
In this context, the synthetic cathinones butylone, buphedrone, 3,4-DMMC, and 4-FMC; and 
the benzofurans 6-APB and 5-APB are NPS that lack information on the mechanisms 
underlying the toxicity reported in clinical cases. Notwithstanding, these drugs are still 
available and consumed. Since oral ingestion is one of the major administration routes for 
this type of stimulants, it is natural that liver represents one of the main targets of NPS 
toxicity, largely due to the first passage effect. Also, due to the important role of liver in 
metabolism, this phenomenon may implicate the generation of more toxic metabolites that 
may exert cytotoxic effects at this level, compromising the good functioning of the organ 
and, therefore, the overall user health. 
Bearing all of this in mind, the aims of the present work were i) to determine the hepatotoxic 
potential of butylone, buphedrone, 3,4-DMMC, 4-FMC, 5-APB, and 6-APB; and ii) to clarify 
the toxicological mechanisms by which the observed effects occur. 
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Materials and Methods 
1. Chemicals and reagents 
Butylone, buphedrone, 6-APB, 5-APB, 3,4-DMMC, and 4-FMC were acquired online at 
sensearomatics.com on April 2013. All drugs were used as provided, in powder form, except 
for 6-APB, which came in pill form and required pulverization before use. Stock solutions of 
all the drugs were made up in Hanks’ balanced salt solution (HBSS, no calcium or 
magnesium) and stored at -20º C. These solutions were thawed and diluted on the days 
that experiments were performed. 
Cell culture reagents were purchased from GIBCO Invitrogen (Alfagene, Lisboa, Portugal) 
and all other reagents were obtained from Sigma-Aldrich (Lisboa, Portugal), unless 
otherwise stated. 
2. Isolation and culture of primary rat hepatocytes 
Primary rat hepatocytes were isolated from male Wistar Han rats weighing between 200-
250 g, purchased from Charles River (Barcelona, Spain). The surgical procedures approved 
by the local ethics committee for the welfare of experimental animals were conducted 
according to national legislation between 10.00 and 11.00 am. The animals were 
anesthetized with isoflurane (IsoFlo®, Abbot Laboratories, Berkshire, UK) and cells were 
isolated through collagenase perfusion method, as previously described by Moldeus (1978). 
Briefly, following the insertion of a cannula in the portal hepatic vein, the liver was perfused 
with an oxygenated Hank’s washing buffer containing the chelator ethylene glycol 
tetraacetic acid (EGTA). After this initial wash, the extracellular concentration of calcium 
decreased significantly, resulting in an irreversible cleavage of the desmosomes (junctional 
complexes). Then, the liver was perfused with a solution of collagenase supplemented with 
its cofactor calcium. The hepatic capsule was then disrupted gently, in order to release the 
isolated cells into a Krebs-Henseleit buffer. This cellular suspension was purified by 3 low-
speed centrifugation cycles (50 x g, 2 minutes, 4º C) and then incubated with 
penicillin/streptomycin (500 U/ml; 500 g/ml) for 30 minutes at 4ºC. Cell viability was then 
estimated by the trypan blue exclusion test, with results always above 85%. The suspension 
with a cellular density of 5 x105 was cultured in Williams’ E medium (Sigma-Aldrich) 
supplemented with 10% heat-inactivated foetal bovine serum (FBS), penicillin/streptomycin 
(100 U/ml; 100 g/ml), 50 g/ml dexamethasone (Sigma-Aldrich), 5 g/ml insulin (Sigma-
Aldrich), 2,5 g/ml fungizone, and 100 g/ml gentamicin. Cells were seeded onto 96-well 
plates, at a density of 50,000 per well in a volume of 100 L, or 6-well plates at a density of 
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5,000,000 per well in a volume of 1 mL and left to adhere overnight, at 37 ºC with a 5% CO2 
atmosphere. 
3. Immortalized cell lines 
Two different hepatic cell lines were used for testing the toxic potential of our compounds, 
HepaRG and HepG2. HepaRG is a cell line derived from a female patient with 
hepatocarcinoma. Cells should be seeded at a low density; upon reaching confluence they 
can transdifferentiate into two types of cells, one that is morphologically similar to human 
primary hepatocytes, and another that resembles bile canaliculus-like structures (Guillouzo 
et al., 2007). Another particularity of the HepaRG cell line is that it retains the ability to 
express all major cytochrome P450 (CYP), with exception of CYP2E1 and CYP2D6, and 
many phase II enzymes, mimicking closely the in vivo situation. HepG2 cells were isolated 
from a male patient with hepatoblastoma, and also express normal hepatocyte function. In 
addition, these cells secrete into the culture medium the majority of plasma proteins and 
retain the capacity to produce and secrete bile acids (Bouma et al., 1989). 
HepaRG cells were acquired from Life Technologies (Invitrogen, France) and were cultured 
in 75 cm2 flasks using Williams’ E medium with L-glutamine supplemented with 10% FBS, 
penicillin/streptomycin (10000 U/ml; 10000g/ml), 5 g/ml insulin (Sigma-Aldrich), and 50 
M hydrocortisone 21-hemisuccinate sodium salt (Sigma-Aldrich). The environmental 
conditions were 37 ºC with an atmosphere with 5% CO2; the medium was changed every 
2-3 days, allowing the cells to grow. Cells were sub-cultured for a maximum of 10 passages 
by tripsinization, and allowed to reach 80% confluence. Upon reaching confluence, the 
differentiation process was started by changing the media to fresh culture media 
supplemented with 2% DMSO (Merck); the medium was changed every two days, for two 
weeks, in order to promote a ratio of hepatic cells 1: biliary cells 1. At the end of this time, 
the cells were seeded into 96-well plates at a density of 144,000 cells per well in a volume 
of 200 L. Cells were left to adhere overnight and were used for cytotoxicity assays on the 
following day. 
HepG2 cells were provided by Prof. Ricardo Dinis-Oliveira (Department of Sciences, 
Advanced Institute of Health Sciences-North, CESPU, CRL, Gandra, Portugal) and cultured 
using DMEM medium supplemented with 10% FBS and 1% penicillin/streptomycin (10000 
U/ml; 10000g/ml), in 75 cm2 flasks. The cells were kept in a humidified 5% CO2 
atmosphere at 37ºC and subjected to regular medium changes (every two-three days). 
Whenever cells reached 80% confluence, they were sub-cultured for no more than 10 
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passages by tripsinization. For the cytotoxicity assays, cells were seeded at a density of 
80,000 cells per well, in a volume of 100 L, in 96-well plates, and left to adhere overnight. 
 
4. Viability assay 
The cytotoxicity of the chosen compounds was evaluated using the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay, which measures cell viability 
indirectly through succinate dehydrogenase activity, an indicator of healthy and functional 
mitochondria. On the day of the experiment, the cells were exposed to a vast range of 
concentrations of all drugs, in triplicates. In each plate, positive (1% Triton X-100) and 
negative controls (culture medium) were also included. The tested concentration range for 
each drug across the different cell models is displayed in Table 2. The MTT results were 
used to calculate the concentrations of each drug to be tested in the further assays. 
Accordingly, the concentrations of each drug producing 20%, 40%, 50% and 70% of the 
maximum effect in the MTT assay (EC20, EC40, EC50 and EC70, respectively) were estimated 
from the respective concentration versus response curves, using the parameters of the best 
fit regression model. 
Table 2 Concentration range (mM) tested for each substance, in the different cell models 
 Butylone Buphedrone 6-APB 5-APB 3,4-DMMC 4-FMC 
Primary rat 
hepatocytes 
0.03770 – 
10.0000 
0.03770 – 
10.0000 
0.03770 – 
23.0000 
0.03770 – 
10.0000 
0.0011 – 
0.7000 
0.03770 – 
10.0000 
HepaRG cells 
0.009600 – 
18.1500 
0.4900 – 
32.0000 
1.1706 – 
14.0000 
0.1100 – 
6.5000 
0.08780 – 
2.0000 
1.4632 – 
30.0000 
HepG2 cells 
1.5937 – 
20.0000 
0.6252 – 
30.0000 
0.1924 – 
30.0000 
0.2926 – 
20.0000 
0.05840 – 
2.0000 
0.5861 – 
30.0000 
 
5. Total (tGSH), reduced (redGSH), and oxidized (GSSG) glutathione 
Samples preparation: Primary rat hepatocytes seeded in 6-well plates were exposed to the 
EC20, EC40, EC50, and EC70 of each testing drug, for a period of 24h, at 37 ºC. After this time, 
the cells were washed with HBSS with calcium and magnesium, and then precipitated using 
5% perchloric acid for 20 minutes, at 4 oC. Cells were scrapped and the obtained 
suspension was centrifuged at 13,000 g for 2 minutes, at 4 ºC. The supernatant was 
collected and stored at -80 ºC until further determinations. The cell pellet was resuspended 
in 1M NaOH and used to quantify protein. 
 
14 
 
The method used to measure tGSH was the 5,5-dithio-bis(2-nitrobenzoic acid) (DTNB)-
GSSG reductase-recycling assay(da Silva et al., 2014a). After thawing, the supernatants 
were neutralized using 0.76 M KHCO3 and centrifuged at 13,000 g for 10 minutes, at 4 ºC. 
Then, 100 L of each supernatant, blanks and standards were transferred to a 96-well plate, 
followed by the addition of 65 L reagent solution (72 mM phosphate buffer, 0.69 mM 
NADPH, and 4 mM DTNB). The plates were incubated for 15 minutes, at 30 ºC, in a multi-
well plate reader (Power Wave XTM, BioTek Instruments, Inc.) and then 40 L of a 10 U/mL 
glutathione reductase solution was added. The absorbance of the samples were further 
read in kinetic mode at 415 nm in order to follow the formation of 5-thio-2-nitrobenzoic acid 
(TNB). The sample results were compared with a standard curve, performed in every 
experiment. The same protocol was used for the quantification of GSSG, with the additional 
step of incubating the samples with 2-vinylpyridine for 1 hour, at 4 ºC. Experimental data 
were normalized to the protein content of each sample. The intracellular redGSH was 
calculated using the formula redGSH = tGSH – 2 x GSSG. 
6. Intracellular adenosine triphosphate (ATP) 
Samples were prepared as described before in ‘5. Total (tGSH), reduced (redGSH), and 
oxidized (GSSG) glutathione’. A bioluminescence method was used for measuring 
intracellular ATP, as previously described. After the neutralization with KHCO3, the samples 
were centrifuged at 13,000 g for 3 minutes, at 4 ºC. Afterwards, 75 L of each supernatant, 
standard, or blank was transferred into a white 96-well plate. Then, 75 L of a luciferin-
luciferase solution (0.15 mM luciferin; 30,000 light units luciferase; 10 mM MgSO4; 50 mM 
glycine;1 mM Tris; 0.55 mM EDTA; 1% BSA) were added and the emitting light intensity 
was measured using a luminescence plate reader (BioTek Instruments, Vermont, USA). 
The results were compared to a standard curve performed in every experiment, and 
normalized to the protein content. 
7. Protein determination 
Protein quantification of samples was performed using the Lowry assay, as established 
previously (Lowry et al., 1951). 
8. Intracellular reactive oxygen (ROS) and nitrogen (RNS) species 
The assessment of intracellular ROS and RNS was performed using the 2’,7’-
dichlorodihydrofluorescein diacetate (DCFH-DA) fluorescence assay, as described by da 
Silva (2014a). Briefly, primary rat hepatocytes seeded in 96-well plates were exposed for 
30 minutes to 10 M DCFH-DA, at 37 ºC, protected from light. Afterwards, the cells were 
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washed using HBSS and incubated with the EC20, EC40, EC50 and EC70 of each tested drug, 
at 37 ºC, for 24 hours. The fluorescence was recorded using a fluorescence microplate 
reader (BioTek Instruments, Vermont, USA), set to 485 nm excitation and 530 nm emission. 
The acquired data was normalized to control conditions (no drug exposure). 
9. Statistical Analysis 
Data obtained in the MTT assay in four independent experiments were fitted to the Logit 
model, chosen based on the goodness-to-fit principle (best fit dosimetric model). The results 
of three different experiments obtained for tGHS, GSSG, ATP, and ROS/RNS 
determinations are presented as mean ± standard error of the mean (SEM). The normality 
of data distribution was analysed using the Kolmogorov-Smirnov test and statistical 
comparison between groups was performed either: i) using one-way analysis of variance 
(ANOVA), followed by Dunn’s multiple comparison test when the results followed a normal 
distribution; or ii) using Kruskal-Wallis test, when the data did not follow a normal 
distribution. All statistical analysis were made using GraphPad Prism software, version 6.07 
(GraphPad Software, San Diego, CA, USA). 
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Results 
1. Synthetic cathinones and benzofurans elicited in vitro hepatotoxicity in a 
concentration-dependent manner 
The cytotoxic effects observed in vitro for all the tested compounds in three different 
hepatocyte models are presented in Figure 8. 
Our data show that the drug-induced cell death is concentration-dependent. The EC50 
values of each compound, for each in vitro model, extrapolated from the regression model 
that best suited the respective data set (i.e. Logit model) are presented in Table 3. The most 
toxic drug for all the evaluated models was 3,4-DMMC, which elicited 50% response at the 
lowest concentrations, when compared with the other drugs. Contrarily, 4-FMC proved to 
be the least toxic drug for primary rat hepatocytes, while for the cell lines HepaRG and 
HepG2, buphedrone presented the highest EC50 values. By analysing the concentration-
response curves and comparing effect concentrations, it is clear that primary rat 
hepatocytes display an increased sensitivity for hepatotoxicity, while HepaRG and HepG2 
cells are more resistant to the toxic effects of these drugs. Therefore, further assays were 
carried out on this model. 
 
Table 3 EC50 values (mM) for the cytotoxicity of butylone, buphedrone, 6-(2-aminopropyl)benzofuran (6-APB), 5-(2-
aminopropyl)benzofuran (5-APB), 3,4-dimethylmethcathinone (3,4-DMMC), and 4-fluoromethcathinone (4-FMC), obtained in 
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, following incubation of each hepatocyte model 
for 24 h, at 37 ºC 
 Butylone Buphedrone 6-APB 5-APB 3,4-DMMC 4-FMC 
Rat hepatocytes 1.2110  
1.5702  1.9360  0.9636  0.1578  2.2127  
HepaRG 4.8073  9.6185  6.0204  2.6170  0.6953  5.5866  
HepG2 7.9213  13.672  8.1816  3.7885  0.6223  9.5679  
Figure 8 Concentration-response curves for butylone, buphedrone, 6-(2-aminopropyl)benzofuran (6-APB), 5-(2-
aminopropyl)benzofuran (5-APB), 3,4-dimethylmethcathinone (3,4-DMMC), and 4-fluoromethcathinone (4-FMC) in primary 
rat hepatocytes, HepaRG and HepG2 cells, following 24 h incubation at 37 ºC. Cell mortality was assessed using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay and data were normalized to positive (100%) 
and negative (0%) controls (n=4). 
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After media aspiration, following primary hepatocyte drug exposures, we verified the 
formation of intracellular black-brown pigments, at the highest concentrations tested. This 
observation occurred before addition of the MTT. 
 
2. Benzofurans and synthetic cathinones induce oxidative stress in primary rat 
hepatocytes 
Induction of oxidative stress is one of the cornerstone toxicity mechanisms of classic 
stimulants, such as amphetamines (Carvalho et al., 2012). Given the verified capacity of 
butylone, buphedrone, 6-APB, 5-APB, 3,4-DMMC, and 4-FMC to induce hepatotoxicity, the 
next step was to determine the role of oxidative stress in this process, by evaluating the 
formation of ROS and RNS in rat hepatocytes 24 h after exposure to the drugs. In addition, 
since GSH is a pivotal first-defence against free radicals, the intracellular levels of GSH and 
GSSG were also measured. For these assays, primary rat hepatocytes were exposed to 
concentrations that elicited mortality of 20%, 40%, 50%, and 70%, as calculated based on 
the MTT assay results. The corresponding drug concentrations are presented in Table 4. 
 
Table 4 Effect concentrations (ECx) of butylone, buphedrone, 6-(2-aminopropyl)benzofuran (6-APB), 5-(2-
aminopropyl)benzofuran (5-APB), 3,4-dimethylmethcathinone (3,4-DMMC), and 4-fluoromethcathinone (4-FMC) that elicit x% 
of effect (i.e. mortality) in the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, following incubation 
of primary hepatocytes for 24 h, at 37 ºC 
 
Figure 9 depicts the results obtained in the DCFH-DA assay utilised for evaluating the 
production of ROS and RNS, after an incubation period of 24h. As observed, 4-FMC elicited 
the greatest production of ROS and RNS. When the cells were exposed to the drug 
concentrations that elicited 20%, 40%, 50%, and 70% of response in the MTT assay, the 
observed results were significantly different from control (p < 0.05 for EC20, p < 0.0001 for 
EC40 and EC50, and p < 0.001 for EC70; Figure 8). Also, 3,4-DMMC caused a significant 
increase in ROS and RNS production, which in this case was dependent on concentration 
(p < 0.01 for EC40, p < 0.001 for EC50, and p < 0.0001 for EC70). Butylone at the 
x (%) Effect concentration (ECx) for the drug with the effectiveness x (mM) 
  Butylone Buphedrone 6-APB 5-APB 3,4-DMMC 4-FMC 
70 2.669 4.151 4.575 2.151 0.232 3.958 
50 1.381 2.831 2.737 1.332 0.167 2.859 
40 0.982 2.343 2.046 1.051 0.142 2.454 
20 0.415 1.469 0.933 0.587 0.096 1.701 
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concentration EC70 also caused a significant increase in ROS and RNS (p < 0.001), as it 
did the EC40 and EC70 of buphedrone (p < 0.05). 
 
Figure 9 Production of reactive oxygen and nitrogen species (ROS and RNS, respectively) in primary rat hepatocytes, after 
exposure to the EC20, EC40, EC50, and EC70 of butylone, buphedrone, 6-(2-aminopropyl)benzofuran (6-APB), 5-(2-
aminopropyl)benzofuran (5-APB), 3,4-dimethylmethcathinone (3,4-DMMC), and 4-fluoromethcathinone (4-FMC) for 24h, at 
37ºC. Fluorescence data from the 2’,7’-dichlorodihydrofluorescein diacetate (DCFH-DA) assay were normalised to negative 
controls (set to 1) and were from four independent experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; compares to 
control. Statistical analysis of data was performed using one-way ANOVA and Dunn’s multiple comparison test. 
 
The results for the quantification of GSH and GSSG are presented in Figure 10.  
Figure 10 Intracellular levels of total (tGSH), reduced (GSH) and oxidized (GSSG) glutathione in primary rat hepatocytes 
following 24h incubation with butylone, buphedrone, 6-(2-aminopropyl)benzofuran (6-APB), 5-(2-aminopropyl)benzofuran 
(5-APB), 3,4-dimethylmethcathinone (3,4-DMMC), and 4-fluoromethcathinone (4-FMC), at 37 ºC. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001; compares to GSH control; & p<0.05, && p<0.01; compares to GSSG control. Statistical analysis 
of data was performed using Kruskal-Wallis test. 
19 
 
Butylone, 5-APB, and 4-FMC, tested at the respective EC50 and EC70 values, caused a very 
significant (p < 0.01 and p < 0.0001, respectively) depletion of GSH when compared to 
control. Buphedrone elicited the most significant thiol disturbance, with EC20 showing the 
least significant GSH decrease (p < 0.01), when compared with all other tested ECx (p < 
0.0001). At the EC50, buphedrone also significantly increased GSSG levels (p < 0.05); while 
4-FMC significantly diminished GSSG levels for all tested concentrations, except EC70 (p < 
0.05). All concentrations of 6-APB, except the EC20, elicited a concentration-dependent 
depletion of GSH; similar to buphedrone, the drug also caused a significant depletion of 
GSSG (p < 0.01), at the EC50. 3,4-DMMC only affected GSH levels at EC70 (p < 0.05), but 
significantly increased GSSG levels both at EC40 and at EC50 (p < 0.01 and p < 0.05, 
respectively). 
3. Synthetic cathinones and benzofurans cause depletion of intracellular ATP 
The ATP is essential for cells to successfully carry out their energy-dependent functions 
and, consequently, to survive. The incubation of primary rat hepatocytes with the EC20, 
EC40, EC50, and EC70 of each NPS for 24h caused an impairment of cell energetics, as 
depicted in Figure 11. 
In general, all drugs concentration-dependently decreased the levels of intracellular ATP. 
These changes were significant for all the concentrations tested, except in the cases of 4-
FMC and 5-APB for which toxicity was only significant when tested at EC50 and EC70 (p < 
0.05). For buphedrone, 6-APB, 5-APB, and 3,4-DMMC a notorious ATP depletion was 
Figure 11 Intracellular adenosine triphosphate (ATP) levels of primary rat hepatocytes following 24h incubation with 
butylone, buphedrone, 6-(2-aminopropyl)benzofuran (6-APB), 5-(2-aminopropyl)benzofuran (5-APB), 3,4-
dimethylmethcathinone (3,4-DMMC) and 4-fluoromethcathinone (4-FMC), at 37 ºC. * (p<0.05), ** (p<0.01), *** (p<0.001), 
**** (p<0.0001) compares to control. Statistical analysis of data was performed using one-way ANOVA and Dunn’s 
multiple comparison test. 
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elicited when drugs were tested at EC70 (p < 0.001 for buphedrone, 6-APB and 5-APB and 
p < 0.0001 for 3,4-DMMC). 
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Discussion 
This work provides the first evidence of hepatotoxicity by the selected synthetic drugs. 
Previous studies have shed some light upon the toxic potential of some other cathinone 
derivatives (Araujo et al., 2015; Valente et al., 2016) and of benzofurans (Nakagawa et al., 
2016). Butylone, buphedrone, 3,4-DMMC, 4-FMC, and the benzofurans 5- and 6-APB are 
substances of abuse that have stimulant effects similar to those of amphetamines and, 
based on the results we presented herein, display similar toxicity mechanisms (Carvalho et 
al., 2012). To the date we started this work, these mechanisms were barely studied, with 
little to no information regarding the toxicological potential of these NPS towards such an 
important organ as the liver. 
We performed cytotoxicity studies in three in vitro models for the hepatocyte. Our results 
provided some clues on how these drugs work. HepG2 cells were previously used to 
successfully demonstrate the hepatotoxicity of other stimulants, namely amphetamines (da 
Silva et al., 2014a; da Silva et al., 2014b; Dias da Silva et al., 2013a; Dias da Silva et al., 
2013b). It is, however, a cell line that expresses very low levels of essential drug-
metabolizing enzymes, such as CYP isoforms (Gerets et al., 2012). The use of HepaRG 
cells – another human hepatoma cell line that display an enzymatic profile more 
representative of the in vivo hepatocyte than HepG2 cells – was therefore of extreme 
relevance since metabolism may severely impact the toxicity of xenobiotics (Gerets et al., 
2012; Rodrigues et al., 2013). In our work, significant differences were verified between the 
concentration-response curves of the tested drugs in both cell lines. The curves obtained 
with HepG2 cells were shifted to the right when compared to those obtained with HepaRG 
cells, and the EC50 values obtained for HepG2 were higher than those for HepaRG cells. 
These findings indicate that HepG2 cells were more resistant to synthetic cathinone and 
benzofuran toxicity than HepaRG. Altogether, the increased sensitivity shown by these cells 
and the expression of a more complete enzymatic profile in HepaRG, may indicate that the 
tested NPS are bioactivated into reactive metabolites or, at least, that metabolism increases 
hepatotoxicity (e.g., through the reactive species formed from e.g. NADPH oxidase activity). 
If this prove to be truth, CYP2B6, which has been described to be involved in the metabolism 
of MDMA and of the isomer 3-FMC (Carvalho et al., 2012; Meyer et al., 2012) may 
contribute to the observed effects since its levels in HepaRG are very considerable, and 
surpass those for HepG2 (Aninat et al., 2006). It is possible that other isoforms also have 
some preponderance, such as CYP1A2 and 3A4, which participate in amphetamine-
derivatives metabolism and have greater expression in HepaRG, compared to HepG2 
(Aninat et al., 2006; Gerets et al., 2012), yet no studies to clarify the involvement of these 
isoforms in metabolism of synthetic cathinones and benzofurans have been conducted.  
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The exception to the observed toxicological differences in both cell lines was 3,4-DMMC; 
for this drug, the EC50 value obtained for HepaRG was slightly higher. Since HepaRG is a 
cell line established from a donor that poorly expressed CYP2D6 and CYP2E1 (Aninat et 
al., 2006), it is conceivable that one or both isoforms are involved in the metabolism of the 
drug. The use of primary rat hepatocytes for evaluating the toxicity of the testing drugs was 
therefore considered essential to address the flaws presented by the employed cell lines.  
The lowest EC50 values were attained for all tested NPS in this in vitro model, indicating 
higher susceptibility to the toxicity induced by the drugs. For 3,4-DMMC the EC50 in primary 
cells was approximately 4x lower, compared to the remaining models, supporting the 
potential relevance of the absent isoforms to the metabolism of the drug. Accordingly, 
studies performed in primary rat hepatocytes, revealed that incubation with quinidine, a 
known CYP2D6 inhibitor, decreased the hepatotoxic potential of some synthetic cathinones 
(Valente et al., 2016), also corroborating our assumption. This CYP isoform has also 
demonstrated to play a pivotal role in the metabolism of designer stimulants, such as 
amphetamines (Carvalho et al., 2012; Pedersen et al., 2013a; Pedersen et al., 2013b), 
among other drugs of abuse (Dias-da-Silva et al., 2015). 
Other causes should be considered in the differential toxic profile of these drugs across the 
tested cell models, for instance the interaction with nuclear receptors that modulate the 
expression of CYP isoenzymes, such as the pregnane X receptor (PXR) and the constitutive 
androstane receptor (CAR); these transcription factors have been found  upregulated in 
HepaRG cells, when compared to HepG2 cells (Aninat et al., 2006), which could impact 
enzyme activity in this particular model. Another factor that should be considered in the 
interpretation of these results are membrane transporters (influx/ efflux pumps). It is not yet 
known which transporters intervene in amphetamines, synthetic cathinones, or benzofurans 
uptake into hepatocytes and/or the drug efflux. Similarly to what happens in the brain, the 
organic cation transporter 1 (OCT1) and the multidrug resistance protein 1 (MDR1), which 
are involved in the influx and efflux of 5-HT and DA (Faber et al., 2003), might also be 
responsible for transporting these substances. It has been shown that HepG2, HepaRG 
and primary hepatocytes possess different levels of these transporters (Le Vee et al., 2006). 
Primary hepatocytes were the cells that expressed the higher and the lower levels of OCT1 
and MDR1, respectively; HepG2 presented the lower expression of OCT1; while HepaRG 
expressed the higher levels of MDR1 (Bachour-El Azzi et al., 2015; Le Vee et al., 2013). 
Therefore, it is plausible that this differential expression of efflux transporters has an 
influence in the present results. In order to test this hypothesis, experiments employing 
specific transporter inhibitors should be carried out in our models to and established the 
comparisons to the observed cytotoxicity profiles. 
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As denoted above, the present results suggest that the most significant differences 
concerning hepatotoxicity among the employed models rely on the activity/content of their 
CYP isoforms, as these toxic effects appear to be magnified with the increased expression/ 
activity of the drug metabolizing enzymes. This might signify that the hepatotoxic effects 
may be due not only to the compounds in itself, but also to their indirect action through toxic 
metabolites. To verify this hypothesis, further experiments should be conducted either i) by 
employing specific enzymatic inhibitors with subsequent evaluation of the impact on the 
toxicity and metabolic profile of butylone, buphedrone, 3,4-DMMC, 4-FMC, 5-APB and 6-
APB; or ii) by directly establishing the toxicological profile of the metabolites of these drugs 
in the same cell models (further comparing the attained results to those obtained for the 
parent drugs). 
It is also possible that interspecies differences account for the discrepancy on the attained 
EC50 values towards the different models, since both cell lines have human origin, but 
primary hepatocytes derive from rat. It has been proven that rat and human hepatocytes 
present different metabolic rates of phase I reactions for amphetamines (rat metabolism is 
faster, compared to humans) and differ in the main metabolic pathways (Green et al., 1986). 
It should also be pondered that there are specific CYP isoforms for rodents and humans 
(Astashkina et al., 2012).  
Also, it should be considered that the immortalization process to which cell lines are 
surrendered, endows cells with distinct characteristics, especially regarding the capacity of 
growth and the extensive lifespan; as the expression profile of several genes has been 
shown to vary between passages, different physiological responses may arise as a 
consequence of aberrant expression of intracellular proteins, loss of polarity, and significant 
decline/absence of important morphological features, such as transporters (Astashkina et 
al., 2012). This can result in data of difficult interpretation across different passages and 
among laboratories. 
One important finding of in our work, occurred during the establishment of the 
concentration-response curves in primary rat hepatocytes; we verified, for the highest 
concentrations tested, the formation of intracellular brown-black pigments. A similar 
occurrence had already been observed for amphetamines and it was attributed to the 
formation of aminochromes (da Silva et al., 2014b). The formation of these aminochromes 
involves metabolism of amphetamines into catechol intermediates that oxidize into the 
corresponding o-quinones. These highly redox active o-quinones will subsequently react 
with GSH, free cysteine and cysteinyl residues on proteins, resulting in significant 
modification of macromolecules, including proteins, lipids and deoxyribonucleic acid (DNA). 
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Also, o-quinones can enter in oxidative cycling, increasing oxidative stress and depleting 
antioxidant cell defences and, afterwards, following oxidations of o-quinones will lead to the 
formation of aminochromes, whose subsequent oxidation leads to the production of 
polymers of melanin type (da Silva et al., 2014a). These pigments have maximal 
absorbance in the same wavelength range of the formazans formed through MTT reduction 
and could, therefore, influence the absorbance readings, in the viability assay. Fortunately, 
this was not problematic since the aminochrome formation only occurred at concentrations 
higher than those for which the maximum effect in the assay (i.e., 100% cell death) had 
already been achieved (concentrations higher than 3.68 mM for butylone, 1.47 mM for 
buphedrone, 10 mM for 6-APB, 5 mM for 5-APB, 0.625 mM for 3,4-DMMC and 10 mM 4-
FMC). If this was not the case, to completely rule out possible interference with the viability 
results, another type of assay would have to be considered for cell death evaluation. 
The formation of ROS and RNS is one of the most prominent toxicity mechanisms of 
amphetamines, both in primary rat hepatocytes and HepG2 cells (da Silva et al., 2014a; 
Pontes et al., 2008). Along with 4-FMC, 3,4-DMMC (the most toxic substance in the MTT 
assay) was also responsible for eliciting one of the most significant increases in ROS and 
RNS at nearly all ECx tested, in primary hepatocytes. Curiously, 4-FMC was the least toxic 
compound for primary rat hepatocytes in the viability assay (although in the current 
determination all drugs were tested at the same effect levels). We expected to observe a 
higher increase of ROS and RNS for butylone, since this drug has a methylenedioxy group 
in its structure, which is likely to be degraded into catechol, further forming highly reactive 
o-quinones. Notwithstanding, significant oxidative stress was only evident at concentrations 
higher than the EC50, suggesting that natural antioxidant defences might be sufficient to 
protect cells from generated deleterious species. This may also be the case of 5-APB and 
6-APB. 
One of the most prominent cell defence against reactive species and xenobiotics is GSH. 
The role of this pivotal antioxidant becomes even more important when considering the 
liver, which is the drug-metabolizing organ by excellence and, therefore, a first target for 
damage induced by noxious compounds (Forman et al., 2009; Yuan and Kaplowitz, 2013). 
In the present work, all the tested stimulants were capable of inducing GSH depletion; this 
is related to an increased production of reactive species, but this effect was not always 
accompanied by the complementary expected increase in GSSG levels. Valente and co-
workers (2016) also verified this discrepancy between GSH and GSSG levels when 
evaluating the hepatotoxic potential of few synthetic cathinones. The GSSG efflux into the 
cell culture medium is promoted to protect cells against excessive oxidative stress, and it 
has already been hypothesised for amphetamines (Carvalho et al., 1996; da Silva et al., 
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2014a). On the other hand, GSH depletion might also be explained by the formation of 
conjugates with metabolites, resembling what also happens with amphetamines (Carvalho 
et al., 2012). This hypothesis waits confirmation. 
The results obtained herein show that all tested synthetic cathinones and benzofurans were 
capable of interfering significantly with ATP homeostasis. The dysfunction of normal cell 
energetics interferes with cell viability since ATP is pivotal for cell survival. The capacity to 
damage normal ATP production has also been verified for MDMA, which can induce 
concentration- and time-dependent ATP depletion in rat hepatocytes (Carvalho et al., 2012). 
Regarding beta-keto-amphetamines hepatotoxicity, Valente and co-workers (2016) also 
registered a decrease in ATP after exposure of isolated rat hepatocytes to the drugs. 
The concentrations of NPS tested here were higher than the concentrations that could be 
quantified in blood sample of an intoxicated patient (Chan et al., 2013; McIntyre et al., 2015; 
Thornton et al., 2012; Usui et al., 2014; Zuba et al., 2013). However, it is well-known that 
liver is exposed to concentrations of amphetamine-like stimulants far higher than the 
concentrations achieved in blood. Considering the aforementioned structural and functional 
similarities between these compounds, it is possible that the same occurs with the drugs 
tested in this work. 
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Conclusion 
Herein it was demonstrated for the first time the concentration-dependent hepatotoxic 
effects of four synthetic cathinones (butylone, buphedrone, 3,4-DMMC and 4-FMC) and two 
benzofurans (6- and 5-APB) in three in vitro models: the human cell lines HepG2 and 
HepaRG, and the primary rat hepatocytes. For all models, 3,4-DMMC proved to be the most 
hepatotoxic compound and primary rat hepatocytes displayed highest sensitivity to all the 
utilized in vitro models. Our findings suggest that the formation of intermediate o-quinones 
may be involved in the metabolism and hepatotoxicity of the tested NPS. Synthetic 
cathinones and benzofurans are marketed without previous testing for human safety and 
wrongly assumed to be safer than classical stimulants. Notwithstanding, we demonstrated 
that all drugs were capable of inducing oxidative stress and depleting ATP in primary rat 
hepatocytes; these toxic mechanisms overlap those for amphetamines and other synthetic 
cathinones. It is important to conduct further studies, which include the investigation of the 
toxic potential of the metabolites of the tested drugs, to better understand the full extent of 
the risks to which consumers of these NPS are exposed to. 
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